Ten years' disease-free survival of advanced epithelial ovarian cancer treated by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy A case report and literature review

被引:2
|
作者
Zhang, Jue [1 ]
Mei, Liejun [2 ]
Wang, Fubing [3 ]
Li, Yan [1 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, 10 Tieyi Rd,Yangfangdian St, Beijing 100038, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Radiol, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Dept Clin Lab, Wuhan 430071, Peoples R China
基金
北京市自然科学基金;
关键词
advanced ovarian cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis; HIPEC; PACLITAXEL; CISPLATIN;
D O I
10.1097/MD.0000000000023404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: One of the most distinctive features of epithelial ovarian cancer is tendency to disseminate into peritoneal cavity to form peritoneal carcinomatosis, indicating advanced disease with poor prognosis. Patient concerns: A fifty-year-old patient had a chief complaint of an abdominal distension lasting 1 month. Diagnoses: The patient was diagnosed with advanced epithelial ovarian cancer with peritoneal carcinomatosis by computed tomography scan, tumor markers, endoscopy examination, and pathology. Interventions: The patient was treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy followed by 8 cycles of systemic chemotherapy. Outcomes: Till March 9, 2020, the patient has disease-free survival over 10 years. Lessons: The application of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy combined with systematic chemotherapy may improve survival dramatically for the patients with epithelial ovarian cancer and peritoneal carcinomatosis and should be considered as an option of a relatively new regime.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Prognostic factors and outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer - A single tertiary institution experience
    Kocic, Milan
    Nikolic, Srdjan
    Zegarac, Milan
    Djurisic, Igor
    Soldatovic, Ivan
    Milenkovic, Petar
    Kocic, Jovana
    JOURNAL OF BUON, 2016, 21 (05): : 1176 - 1183
  • [32] Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Le Saux, Olivia
    Decullier, Evelyne
    Freyer, Gilles
    Glehen, Olivier
    Bakrin, Naoual
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2019, 35 (01) : 652 - 657
  • [33] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience
    Koenigsrainer, Ingmar
    Horvath, Philipp
    Struller, Florian
    Grischke, Eva Maria
    Wallwiener, Diethelm
    Koenigsrainer, Alfred
    Beckert, Stefan
    LANGENBECKS ARCHIVES OF SURGERY, 2014, 399 (05) : 589 - 594
  • [34] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at first recurrence, or later?
    Gonzalez Bayon, L.
    Steiner, M. A.
    Vasquez Jimenez, W.
    Asencio, J. M.
    Alvarez de Sierra, P.
    Atahualpa Arenas, F.
    Rodriguez del Campo, J.
    Garcia Sabrido, J. L.
    EJSO, 2013, 39 (10): : 1109 - 1115
  • [35] Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer A Randomized Clinical Trial
    Lim, Myong Cheol
    Chang, Suk-Joon
    Park, Boram
    Yoo, Heon Jong
    Yoo, Chong Woo
    Nam, Byung Ho
    Park, Sang-Yoon
    JAMA SURGERY, 2022, 157 (05) : 374 - 383
  • [36] Risk factors for postoperative delayed gastric emptying in ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Cui, Guang-Xia
    Wang, Zi-Jun
    Zhao, Jin
    Gong, Ping
    Zhao, Shuai-Hong
    Wang, Xiao-Xue
    Bai, Wen-Pei
    Li, Yan
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (18) : 4644 - 4653
  • [37] Re: "Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase II trial." - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study.
    Ansaloni, Luca
    De Iaco, Pierandrea
    Frigerio, Luigi
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 279 - 281
  • [38] Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
    Acs, Miklos
    Herold, Zoltan
    Szasz, Attila Marcell
    Mayr, Max
    Haeusler, Sebastian
    Piso, Pompiliu
    CANCERS, 2022, 14 (14)
  • [39] Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study
    Ceresoli, Marco
    Verrengia, Apollonia
    Montori, Giulia
    Busci, Luisa
    Coccolini, Federico
    Ansaloni, Luca
    Frigerio, Luigi
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (03)
  • [40] Review of the Outcomes of Ovarian Cancer Treated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy
    Langstraat, Carrie
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (04)